Search

Your search keyword '"Dicecca R"' showing total 4 results
Start Over Author "Dicecca R"
4 results on '"Dicecca R"'

2. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer

Author

Walia, G., primary, Lu, M., additional, Bourla, A., additional, Santos, E., additional, Schulze, K., additional, Cabili, M., additional, Williams, E., additional, Mirkovic, N., additional, Dicecca, R., additional, Lee, S., additional, Fang, B., additional, Schwartzberg, L., additional, Herbst, R., additional, and Chiang, A., additional

Published
2021
Full Text
View/download PDF

4. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Author

Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, and Benes CH

Subjects
Acrylamides, Aminopyridines, Anaplastic Lymphoma Kinase, Aniline Compounds, Biomarkers, Tumor metabolism, Biopsy, Crizotinib, ErbB Receptors genetics, ErbB Receptors metabolism, Erlotinib Hydrochloride therapeutic use, Feeder Cells cytology, Fluorescent Antibody Technique methods, Gene Expression, High-Throughput Screening Assays, Humans, Keratin-18 genetics, Keratin-18 metabolism, Keratin-8 genetics, Keratin-8 metabolism, Lactams, Lactams, Macrocyclic therapeutic use, Lung Neoplasms genetics, Lung Neoplasms metabolism, Lung Neoplasms pathology, Mutation, Neoplasms classification, Neoplasms genetics, Neoplasms pathology, Piperazines therapeutic use, Pyrazoles therapeutic use, Pyridines therapeutic use, Receptor Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases metabolism, Tumor Cells, Cultured, Antineoplastic Agents therapeutic use, Biomarkers, Tumor genetics, Lung Neoplasms drug therapy, Neoplasms drug therapy, Precision Medicine methods, Primary Cell Culture methods
Abstract

Personalized cancer therapy is based on a patient's tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient's living cancer cells that could complement these approaches. We present methods for developing cell cultures from tumor biopsies and identify the types of samples and culture conditions associated with higher efficiency of model establishment. Toward the application of patient-derived cell cultures for personalized care, we established an immunofluorescence-based functional assay that quantifies cancer cell responses to targeted therapy in mixed cell cultures. Assaying patient-derived lung cancer cultures with this method showed promise in modeling patient response for diagnostic use. This platform should allow for the development of co-clinical trial studies to prospectively test the value of drug profiling on tumor-biopsy-derived cultures to direct patient care., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results